NKTR
NASDAQ · Pharmaceuticals
Nektar Therapeutics
$72.22
-2.62 (-3.50%)
Financial Highlights (FY 2026)
Revenue
198.75M
Net Income
-240,216,024
Gross Margin
68.8%
Profit Margin
-120.9%
Rev Growth
-1.2%
D/E Ratio
1.51
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 68.8% | 68.8% | 33.1% | 33.1% |
| Operating Margin | -106.9% | -96.2% | 30.6% | 35.1% |
| Profit Margin | -120.9% | -114.8% | 23.0% | 25.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 198.75M | 201.06M | 246.52M | 245.87M |
| Gross Profit | 136.78M | 138.37M | 81.64M | 81.42M |
| Operating Income | -212,425,036 | -193,406,709 | 75.50M | 86.21M |
| Net Income | -240,216,024 | -218,709,581 | 56.66M | 62.08M |
| Gross Margin | 68.8% | 68.8% | 33.1% | 33.1% |
| Operating Margin | -106.9% | -96.2% | 30.6% | 35.1% |
| Profit Margin | -120.9% | -114.8% | 23.0% | 25.3% |
| Rev Growth | -1.2% | -1.2% | +15.2% | +17.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 595.18M | 595.18M | 257.51M | 280.38M |
| Total Equity | 393.90M | 393.90M | 292.45M | 319.03M |
| D/E Ratio | 1.51 | 1.51 | 0.88 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -204,346,275 | -196,387,416 | 106.98M | 112.84M |
| Free Cash Flow | — | — | 45.61M | 47.98M |